Cited by 76Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchGenetic Associations and Epidemiology

Deleterious ABCA7 mutations and transcript rescue mechanisms in early onset Alzheimer’s disease

Open access
On behalf of the European Early-Onset Dementia (EU EOD) consortium, De Roeck, Arne, Van den Bossche, Tobi, van der Zee, Julie, Verheijen, Jan, De Coster, Wouter, Van Dongen, Jasper, Dillen, Lubina +37 more·2017·Acta Neuropathologica

Abstract

Premature termination codon (PTC) mutations in the ATP-Binding Cassette, Sub-Family A, Member 7 gene (ABCA7) have recently been identified as intermediate-to-high penetrant risk factor for late-onset Alzheimer's disease (LOAD). High variability, however, is observed in downstream ABCA7 mRNA and protein expression, disease penetrance, and onset age, indicative of unknown modifying factors. Here, we investigated the prevalence and disease penetrance of ABCA7 PTC mutations in a large early onset AD (EOAD)-control cohort, and examined the effect on transcript level with comprehensive third-generation long-read sequencing. We characterized the ABCA7 coding sequence with next-generation sequencing in 928 EOAD patients and 980 matched control individuals. With MetaSKAT rare variant association analysis, we observed a fivefold enrichment (p = 0.0004) of PTC mutations in EOAD patients (3%) versus controls (0.6%). Ten novel PTC mutations were only observed in patients, and PTC mutation carriers in general had an increased familial AD load. In addition, we observed nominal risk reducing trends for three common coding variants. Seven PTC mutations were further analyzed using targeted long-read cDNA sequencing on an Oxford Nanopore MinION platform. PTC-containing transcripts for each investigated PTC mutation were observed at varying proportion (5-41% of the total read count), implying incomplete nonsense-mediated mRNA decay (NMD). Furthermore, we distinguished and phased several previously unknown alternative splicing events (up to 30% of transcripts). In conjunction with PTC mutations, several of these novel ABCA7 isoforms have the potential to rescue deleterious PTC effects. In conclusion, ABCA7 PTC mutations play a substantial role in EOAD, warranting genetic screening of ABCA7 in genetically unexplained patients. Long-read cDNA sequencing revealed both varying degrees of NMD and transcript-modifying events, which may influence ABCA7 dosage, disease severity, and may create opportunities for therapeutic interventions in AD.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00401-017-1714-x

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
On behalf of the European Early-Onset Dementia (EU EOD) consortium, De Roeck, A., Van den Bossche, T., van der Zee, J., Verheijen, J., De Coster, W., Van Dongen, J., Dillen, L., Baradaran-Heravi, Y., Heeman, B., Sanchez-Valle, R., Lladó, A., Nacmias, B., Sorbi, S., Gelpi, E., Grau-Rivera, O., Gómez-Tortosa, E., Pastor, P., Ortega-Cubero, S., Pastor, M. A., Graff, C., Thonberg, H., Benussi, L., Ghidoni, R., Binetti, G., de Mendonça, A., Martins, M., Borroni, B., Padovani, A., Almeida, M. R., Santana, I., Diehl-Schmid, J., Alexopoulos, P., Clarimon, J., Lleó, A., Fortea, J., Tsolaki, M., Koutroumani, M., Matěj, R., Rohan, Z., De Deyn, P., Engelborghs, S., Cras, P., Van Broeckhoven, C., & Sleegers, K.
Affiliations
  • University of Antwerp (BE)
  • Hospital Clínic de Barcelona (ES)
  • University of Florence (IT)
  • Karolinska University Hospital (SE)
  • Centro San Giovanni di Dio Fatebenefratelli (IT)
  • University of Lisbon (PT)
  • University of Brescia (IT)
  • Centro de Neurociências e Biologia Celular (PT)
  • Technical University of Munich (DE)
  • Universitat Autònoma de Barcelona (ES)
  • Aristotle University of Thessaloniki (GR)
  • Charles University (CZ)
Corresponding author
Sleegers, Kristel
Venue
Acta Neuropathologica
Published
2017-04-27
Volume
134
Issue
3
Pages
475-487
ISSN
  • 0001-6322 (ISSN-L)
  • 1432-0533
OpenAlex
W2609657566
Cited by
74
References
52
Citations by year
2026: 3 · 2025: 6 · 2024: 10 · 2023: 10 · 2022: 14 · 2021: 8 · 2020: 6 · 2019: 8 · 2018: 7 · 2017: 2
FWCI
4.65
Type
journal article
Language
en
Open access
Locations
  • Acta Neuropathologica (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Dipòsit Digital de Documents de la UAB (Universitat Autònoma de Barcelona) (submittedVersion, cc-by)
  • LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, cc-by)
  • Florence Research (University of Florence) (submittedVersion, cc-by)
  • mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
  • MPG.PuRe (Max Planck Society) (submittedVersion, other-oa)
  • VUBIR (Vrije Universiteit Brussel) (submittedVersion)
Funders
  • Seventh Framework Programme (305299)
  • BELSPO (NeuroBrainNet)
  • SAO-FRA (S16031, S13023)
  • Flemish Government initiated Flanders Impulse Program on Networks for Dementia Research (VIND)
  • Flemish Government Initiated Methusalem Excellence Program
  • FWO (1S44216N)
  • VIB (Technology Fund)
  • University of Antwerp Research Fund
  • VLAIO (Hermesfonds)
  • Generalitat de Catalunya (2014SGR-0235)
  • Instituto de Salud Carlos III (PI12/01311)
  • Spanish Ministry of Economy and Competitiveness ISCIII (PI14/00282)
  • European Regional Development Fund
  • Italian Ministry of Health (RF-2010-2319722, Ricerca Corrente)
  • Fondazione Cassa di Risparmio di Pistoia e Pescia (2014.0365)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
Keywords
ABCA7, early-onset Alzheimer's disease, nonsense-mediated mRNA decay, alternative splicing, disease penetrance, rare variant association, genetic screening
MeSH terms
Adult, Aged, Alzheimer Disease, Female, Humans, Male, Middle Aged, Mutation, Age of Onset, ATP-Binding Cassette Transporters, Genetic Predisposition to Disease, Polymorphism, Single Nucleotide, Genetic Association Studies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review